KR100967832B1 - Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient - Google Patents
Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient Download PDFInfo
- Publication number
- KR100967832B1 KR100967832B1 KR1020090090408A KR20090090408A KR100967832B1 KR 100967832 B1 KR100967832 B1 KR 100967832B1 KR 1020090090408 A KR1020090090408 A KR 1020090090408A KR 20090090408 A KR20090090408 A KR 20090090408A KR 100967832 B1 KR100967832 B1 KR 100967832B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- lotus root
- composition
- present
- gastritis
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 68
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 67
- 239000004480 active ingredient Substances 0.000 title claims abstract description 22
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 6
- 235000003261 Artemisia vulgaris Nutrition 0.000 title description 5
- 235000003826 Artemisia Nutrition 0.000 title 1
- 244000030166 artemisia Species 0.000 title 1
- 235000009052 artemisia Nutrition 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 9
- 239000004599 antimicrobial Substances 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 abstract description 44
- 235000013305 food Nutrition 0.000 abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 17
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 12
- 201000005917 gastric ulcer Diseases 0.000 abstract description 9
- 241001675349 Artemisia dubia var. asiatica Species 0.000 abstract 5
- 201000008225 Klebsiella pneumonia Diseases 0.000 abstract 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 240000006891 Artemisia vulgaris Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 241001435059 Artemisia argyi Species 0.000 description 2
- 235000010894 Artemisia argyi Nutrition 0.000 description 2
- 241000092668 Artemisia capillaris Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000209477 Nymphaeaceae Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 244000065027 Artemisia princeps Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- -1 n-nucleic acid Chemical compound 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물, 예방 또는 개선용 식품 조성물 또는 항균 조성물에 관한 것으로 더욱 상세하게는, 애엽 추출물과 연근 추출물이 1대 0.1 내지 10의 비율로 혼합된 혼합조성물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물 또는 클렙시엘라 뉴모니에에 대하여 항균작용을 하는 항균 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating gastritis, a food composition for preventing or improving, or an antimicrobial composition containing the leaf extract and lotus root extract as an active ingredient. The present invention relates to a pharmaceutical composition for preventing or treating gastritis or an antimicrobial composition having an antimicrobial activity against Klebsiella pneumoniae containing a mixed composition mixed at a ratio of 10 as an active ingredient.
고도로 산업화된 사회에서 바쁘게 살아가는 현대인들은 각종 스트레스에 시달리고 있으며, 이러한 스트레스는 각종 질환을 유발시킨다. 특히, 위염 및 위궤양은 소화기 계통의 질환 중에서 가장 대표적인 질환으로서 현재 소화성 궤양의 발생 빈도는 점점 증가하고 있다. 미국에서는 매년 50만 명의 새로운 궤양 환자가 발생 하고, 매년 400만 명이 재발하고 있다. 서구라파에서는 전 인구의 10 % 정도가 일생에 한번은 위궤양이나 십이지장궤양으로 고생을 하고, 우리나라에서도 소화성 궤양 환자가 점점 증가하여 그 발생 빈도가 구미의 각국과 비슷하다. Modern people who are busy living in a highly industrialized society suffer from various stresses, and these stresses cause various diseases. In particular, gastritis and gastric ulcer are the most representative diseases of the gastrointestinal system, and the incidence of peptic ulcer is increasing at present. In the United States, half a million new cases of ulcer occur each year, with four million recurring every year. In Western Europe, about 10% of the population suffers from gastric ulcer or duodenal ulcer once in a lifetime, and the incidence of peptic ulcer patients in Korea is increasing and its frequency is similar to that of Western countries.
위염이란 위 점막에 염증이 생기는 것을 말한다. 스트레스성 위염이란 스트레스로 인한 소화불량으로 위산이나 음식물로부터 위를 보호하는 위점막에 염증이 생기는 것을 말한다. 초기에 통증을 잘 느끼지 못하므로 만성위염으로 발전하는 경우가 많다. 위장은 제2의 뇌라고 할 만큼 소화기관은 뇌와 밀접한 관계가 있다.Gastritis is an inflammation of the gastric mucosa. Stress gastritis is an indigestion caused by stress, which causes inflammation of the gastric mucosa that protects the stomach from stomach acid or food. In the early stages of pain do not feel well, often develop chronic gastritis. The gastrointestinal tract is said to be the second brain, so the digestive organs are closely related to the brain.
중추신경계에 스트레스성 자극을 주었을 때 위의 기능에 영향을 주어 위산 분비가 증가하고 운동성이 현저히 떨어지며 이는 스트레스에 대한 위 감각의 비정상적인 예민성, 정신사회적 요소, 위장관 운동이상 등이 원인이 될 수 있다. 육체적, 정신적 스트레스는 시상하부의 변화를 일으켜서 위 점막의 미세순환장애와 저혈압을 야기함으로써 위궤양을 유발한다고 보고된 바 있다.(Tadaoki Mizuno, Yokohama Med. Bull., 38(3,4), 87-97, 1987). Stressful stimulation of the central nervous system affects the function of the stomach, leading to increased gastric acid secretion and significantly reduced mobility, which may be caused by abnormal sensitivity of the stomach sensation to stress, psychosocial factors, and gastrointestinal dyskinesia. . Physical and mental stress has been reported to cause gastric ulceration by altering the hypothalamus, leading to microcirculation disorders and hypotension of the gastric mucosa (Tadaoki Mizuno, Yokohama Med. Bull., 38 (3,4), 87-). 97, 1987).
스트레스성 위염의 경우 의학적으로는 위장운동 촉진제, 제산제, 위산 억제제, 정신과 약물 등을 처방하고 있다. 이러한 소화성 궤양제에서 흔히 쓰이는 제산제인 중탄산나트륨(Sodium bicarbonate), 탄산칼슘(Calcium carbonate)은 제산 능력은 강하나 위산중화 후 발생하는 이산화탄소에 의해 2차적인 위벽의 자극을 발생하여 위에서 산이 더 발생하며, 나트륨(sodium) 및 칼슘(calcium)을 다량 복용하게 되어 알칼리혈증, 고칼슘혈증 및 고혈압과 같은 부작용이 있게 된다. 또한 산 분비 억제제인 (H 2 antagonist) 시메테딘(cimetidine)의 경우는 노인에 있어서 중추신 경을 억제하기도하고, 항안드로겐(anti-androgen)효과로 유방비대, 성욕감퇴등의 부작용과 다른 약물의 독성을 증가시키는 작용도 한다. 이에 대해 프로톤 펌프 차단제(Proton pump inhibitor), 위점막보호제(Cytoprotective) 등이 개발되어 있으나 장기 복용에 대한 부작용 및 축적 작용의 개선과 더욱 효과적이고 안전한 약물개발에 대한 필요성이 증대함에 따라 민간이나 한방에서 응용된 약물로 그 치료제를 개발하려는 노력이 진행되고 있는 실정이다.In the case of stress gastritis, medical prescriptions include gastrointestinal stimulants, antacids, gastric acid inhibitors, and psychiatric drugs. The antacids commonly used in these peptic ulcers are sodium bicarbonate and calcium carbonate, which have strong antacid abilities but cause secondary gastric wall irritation by carbon dioxide generated after neutralizing gastric acid. High doses of sodium and calcium have side effects such as alkalosis, hypercalcemia and hypertension. In addition, the acid secretion inhibitor (H 2 antagonist) cimetidine suppresses the central nervous system in the elderly, and has anti-androgen effects and other side effects such as breast enlargement and decreased libido. It also increases the toxicity of. Proton pump inhibitors and cytoprotective have been developed for this purpose, but the improvement of side effects and accumulation effects on long-term use and the necessity for more effective and safe drug development are increasing in private and oriental medicine. Efforts are being made to develop the drug with the applied drug.
일반적으로 병원성 미생물에 의한 직접 혹은 간접적인 피해는 경제, 환경, 의학적으로 많은 문제를 일으키고 있다. 특히, 식품 산업에서의 식품 유통 과정 중의 부패로 인한 손실, 농산업에서의 농작물에 대한 과량의 화학 살충제의 사용으로 인한 인체의 유해성 및 환경오염, 항생제의 오남용으로 인한 항생제 내성 균주의 출연 등은 이미 사회 전반에서 고질적인 문제가 되고 있다. 이런 현실에서 식물 등에서 분리된 천연 생리 활성 물질들은 병원성 세균, 진균 등의 넓은 범위에서 항생 활성을 나타내지만, 환경 친화적으로 사용할 수 있다는 점에서 새로운 대체 물질로서의 개발이 시급한 실정이다.In general, the direct or indirect damage caused by pathogenic microorganisms causes many economic, environmental and medical problems. In particular, losses due to corruption in the food distribution process in the food industry, the harmful effects of humans and environmental pollution from the use of excessive chemical pesticides on crops in the agricultural industry, and the appearance of antibiotic-resistant strains due to the misuse of antibiotics It becomes a chronic problem in the first half. In this reality, natural bioactive substances isolated from plants exhibit antibiotic activity in a wide range of pathogenic bacteria, fungi, etc., but development of new alternatives is urgent in that they can be used environmentally.
클렙시엘라 뉴모니에는 그람음성간균으로 장내세균과에 속한다. 최초 폐렴환자로부터 분리되어 pneumoniae란 이름이 붙여졌다. 장관에 서식하는 상주균이나 기타 기관에 감염이 되면 대장균과 마찬가지로 염증을 일으킨다. 요로감염, 폐렴 등의 원인균으로 알려져 있다.Klebsiella pneumoniae is a Gram-negative bacillus belonging to the intestinal bacteria family. It was isolated from the first pneumonia patient and was named pneumoniae. Infection with resident bacteria or other organs in the intestine causes inflammation, just as with E. coli. It is known as a causative agent of urinary tract infections and pneumonia.
국화과에 속하는 쑥(Artemisia Linne)은 북반구에 200여종이 있고 국내에는 38종이 분포되어 있는 것으로 보고되어 있으며 대표적으로 비쑥, 물쑥, 산쑥, 사철쑥, 황해쑥, 인진쑥, 뺑쑥, 덤불쑥 등을 포함하며, 줄기와 잎자루는 약용이며, 어린 잎은 식용, 보통 잎은 뜸쑥을 만들 때 사용한다. 흰털은 긁어서 인주를 만드는데 사용하기도 하고, 백호(白蒿), 봉애(蓬艾), 애초(艾草) 또는 봉호(蓬蒿)라고도 불리운다. 쑥은 한방에서 코피, 자궁출혈 등의 지혈약으로 쓰이고, 소화, 하복부 진통, 구충 및 악취제거 등에 효과가 있으며, 변비, 신경통, 냉병, 부인병 및 천식에 효과가 있다고 하여, 쑥차로 음용되어 왔다.Artemisia Linne belonging to the Asteraceae family has more than 200 species in the northern hemisphere and 38 species in Korea are reported. Stems and petioles are medicinal, young leaves are edible and ordinary leaves are used to make moxa. White hair is used to make a scratch by making a white rice, and it is also called white tiger (白 애), Bongae (蓬 艾), the beginning (艾草) or Bongho (蓬蒿). Mugwort is used as a hemostatic drug such as nosebleeds, uterine bleeding in oriental medicine, and is effective in digestion, lower abdominal pain, elimination of hookworms and odors, and is said to have an effect on constipation, neuralgia, cold sickness, women's diseases and asthma, and has been used as mugwort tea.
연(Nelumbo nucifera Gaertner)은 수련과에 속하는 다년생 수생식물로써, 전 세계에 널리 분포하며, 관상용, 식용 및 약용으로 사용하여왔으며, 잎, 꽃, 연자육, 연근 등 거의 모든 부분을 식용으로 사용하고 있다 (Luo X. et al., Analytica Chemica Acta, 538, pp129-133, 2005). 전통적으로 잎은 하엽이라 하여 해열, 해독작용에 사용하여 왔으며, 종자와 과육은 강장, 지혈약, 야뇨증, 부인병에 사용하여 왔으며, 뿌리는 해열독, 소어혈, 일체혈증, 요혈, 장출혈 및 지혈에 사용하여 왔다 (김영배, 한약(생약)규격집(KHP), pp500, 2000 ; 김창민, 중약대사전, pp5956-5959, 1998). Lotus (Nelumbo nucifera Gaertner) is a perennial aquatic plant belonging to the water lily family. It is widely distributed all over the world, and has been used for ornamental, food and medicinal purposes. (Luo X. et al., Analytica Chemica Acta, 538, pp129-133, 2005). Traditionally, the leaves have been used for fever and detoxification because they are lower lobes. Seeds and flesh have been used for tonic, hemostatic drugs, nocturnal enuresis, and gynecological diseases. Roots have antipyretic poisons, small fish, monolepsy, bleeding, intestinal bleeding, and hemostasis. (KHP), pp500, 2000; Kim Chang-min, Chinese Medicinal Dictionary, pp5956-5959, 1998).
그러나 지금까지 연근추출물 및 쑥 추출물의 혼합조성믈이 스트레스성 위염 발생을 억제한다는 것은 보고된 바가 없으며, 클렙시엘라 뉴모니에에 대한 항균효과 역시 보고된 바가 없다.However, it has not been reported that the mixed composition of lotus root extract and mugwort extract inhibits the occurrence of stress gastritis, and antimicrobial effects on Klebsiella pneumoniae have not been reported.
본 발명자들은 스트레스성 위염에 효능이 있는 물질에 대하여 연구하던 중 애엽 추출물과 연근 추출물을 혼합한 조성물이 스트레스성 위염을 예방 또는 치료 효과가 탁월한 것을 발견하고 또한 이 조성물이 클렙시엘라 뉴모니에에 대하여 항균활성까지 가지는 것을 발견하여 본 발명을 완성하였다.The inventors of the present invention, while studying a substance that is effective for stress gastritis, found that the composition of the leaf extract and lotus root extract was excellent in preventing or treating stress gastritis, and the composition was also found in Klebsiella pneumoniae. The present invention was found to have antimicrobial activity.
따라서 본 발명의 목적은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Therefore, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating gastritis, which comprises a leaf extract and lotus root extract as an active ingredient.
본 발명의 다른 목적은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving gastritis, which contains a leaf extract and lotus root extract as an active ingredient.
본 발명의 다른 목적은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 클렙시엘라 뉴모니에에 대하여 항균작용을 하는 항균 조성물을 제공하는 것이다.Another object of the present invention is to provide an antimicrobial composition having an antimicrobial action against Klebsiella pneumoniae containing leaf extract and lotus root extract as an active ingredient.
상기의 목적을 달성하기 위하여 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for gastritis prevention or treatment containing the leaf extract and lotus root extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 개선용 식품 조성물을 제공한다.In order to achieve the other object of the present invention, the present invention provides a food composition for preventing or improving gastritis containing a leaf extract and lotus root extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 클렙시엘라 뉴모니에에 대하여 항균작용을 하는 항균 조성물을 제공한다.In order to achieve another object of the present invention, the present invention provides an antimicrobial composition having an antimicrobial activity against Klebsiella pneumoniae containing leaf extract and lotus root extract as an active ingredient.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방, 개선 또는 치료용 조성물을 제공한다.The present invention provides a composition for the prevention, improvement or treatment of gastritis, comprising the leaf extract and lotus root extract as an active ingredient.
본 발명의 애엽은 황해쑥(Artemisia argyi Lev. et Vant.)과 쑥(A. princeps Pamp. var. orientalis Hara) 또는 산쑥(A. montana Pampani)의 잎이나 어린줄기를 말한다. 유사식물로 인진호(A. capillaris Herba)와 한인진(A. iwayomogii Herba)이 있는데, 인진호는 식물명으로 사철쑥(A. capillaris Thunberg.)의 지상부를 말하며, 한인진은 더위지기(A. iwayomogi Kitamura)의 지상부를 일컫는다(대한약전외 한약(생약)규격집, 식품의약품안전청, 2002).The leaf of the present invention refers to the leaves or young stems of Artemisia argyi Lev. Et Vant. And mugwort (A. princeps Pamp. Var. Orientalis Hara) or A. montana Pampani. Similar plants include A. capillaris Herba and A. iwayomogii Herba. Injin is the name of the plant on the ground of A. capillaris Thunberg. (Korean herbal medicine and herbal medicine standard collection, Korea Food and Drug Administration, 2002).
한편, 연근은 수련과에 속하는 다년생 초본인 연꽃(학명 Nelumbo nucifera Gaertn)의 뿌리줄기를 말한다. 주성분은 당질로서 대부분이 녹말이다. 아미노산으로는 아스파라긴산, 이르기닌, 티로신이 함유되어 있으며 레시틴, 펙틴도 많다. 또한 일반 식물에는 적은 비타민B12가 함유되어 있는 것이 특색이다. 연근은 해열독, 소어혈, 일체혈증, 요혈, 장출혈 및 지혈에 사용하여 왔다.On the other hand, lotus root refers to the root stem of the perennial herbaceous lotus (nelumbo nucifera Gaertn) belonging to the water lily family. The main ingredient is sugar, most of which is starch. Amino acids contain aspartic acid, ylangine and tyrosine, as well as lecithin and pectin. It is also characterized by low levels of vitamin B12 in common plants. Lotus root has been used for fever poisoning, bovine blood, monoemia, bleeding, intestinal bleeding and hemostasis.
본 발명의 애엽추출물 및 연근 추출물은 당업계에 공지된 용매 추출법에 의해 제조할 수 있다. 추출용매로는 예를 들어, 물, 에탄올 및 메탄올과 같은 탄소수 1 내지 6개의 알코올, 아세톤, 에틸아세테이트, n-핵산, 디에틸에테르, 아세톤, 벤젠과 같은 유기용매 중에서 선택된 어느 하나 또는 이들의 혼합용매를 사용할 수 있다. 바람직하게는, 물, 탄소수 1개 내지 6개의 알코올 및 이들의 혼합용매로 이루어진 군에서 선택된 어느 하나의 용매로 추출할 수 있다.Leaf extract and lotus root extract of the present invention can be prepared by a solvent extraction method known in the art. Examples of the extraction solvent include any one selected from alcohols having 1 to 6 carbon atoms such as water, ethanol and methanol, organic solvents such as acetone, ethyl acetate, n-nucleic acid, diethyl ether, acetone, and benzene, or a mixture thereof. Solvents may be used. Preferably, the solvent may be extracted with any one solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms, and mixed solvents thereof.
가장 바람직하게는 상기 추출용 용매는 물일 수 있다. 추출방법은 상기 용매를 사용하여 냉침, 온침, 가열 등 통상의 추출방법이 사용 가능하다. 물을 이용한 추출시 애엽 또는 연근과 물의 비율은 특별히 한정되지 아니하나, 애엽 또는 연근에 물을 중량기준 3배 내지 20배로 첨가할 수 있다. 바람직하게는 추출효율을 증가시키기 위하여 애엽 또는 연근에 대하여 물을 8배 내지 12배로 첨가할 수 있다. 추출시 온도는 추출성분의 파괴가 일어나지 않는 한 특별히 제한되지 아니하나 바람직하게는 4℃ 내지 120℃일 수 있다. 가장 바람직하게는 18℃ 내지 30℃일 수 있다. 추출시간은 추출온도 및 추출용매에 따라 달라지나 0.5시간 내지 48시간, 바람직하게는 20시간 내지 30시간동안 추출한다.Most preferably, the extraction solvent may be water. As the extraction method, conventional extraction methods such as cold needle, warm needle and heating may be used using the solvent. When the extraction using water is not particularly limited to the ratio of the leaf or lotus root and water, it can be added to the leaf or lotus root 3 to 20 times by weight. Preferably, in order to increase the extraction efficiency, water may be added in an amount of 8 to 12 times to the root leaf or lotus root. The temperature at the time of extraction is not particularly limited as long as the extraction component is not destroyed, but preferably 4 ° C to 120 ° C. Most preferably 18 ° C. to 30 ° C. The extraction time depends on the extraction temperature and the extraction solvent but is extracted for 0.5 hours to 48 hours, preferably 20 hours to 30 hours.
추출에 사용되는 애엽 또는 연근은 수확한 후 세척하여 그대로 사용하거나 건조하여 사용할 수 있다. 건조방법으로는 양건, 음건, 열풍건조 및 자연 건조하는 방법을 모두 사용할 수 있다. 또한, 추출효율을 증대시키기 위해 애엽 또는 연근을 분쇄기로 분쇄하여 사용할 수 있다.The leaflets or lotus roots used for extraction can be harvested, washed and used as is or dried. As a drying method, both dry, shade, hot air drying and natural drying can be used. In addition, in order to increase the extraction efficiency can be used by grinding the leaflets or lotus root with a grinder.
본 발명의 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 여과지를 이용한 침전물 분리, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리, 탈색과정 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 애엽 또는 연근 추출물에 포함된다. 바람직하게는 본 발명의 추출물은 추가로 여과지를 이용한 침전물 분리과정 및 농축과정을 거쳐 사용될 수 있다. 상기 농축과정은 공지의 농축장치를 이용하거나, 100℃이하의 온도에서 중탕하여 농축할 수 있다.The extract of the present invention includes not only the extract by the aforementioned extraction solvent, but also an extract that has undergone a conventional purification process. For example, sediment separation using filter paper, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), decolorization process, etc. Fractions obtained through various purification methods additionally carried out are also included in the extract of Lotus leaf or lotus root of the present invention. Preferably, the extract of the present invention may be further used after the sediment separation process and concentration process using a filter paper. The concentration process can be concentrated using a known concentration apparatus, or by bathing at a temperature of 100 ℃ or less.
본 발명의 일실시예에서는 애엽 또는 연근 100g을 물 또는 80% 에탄올 1L에 넣어 24시간동안 24℃에 방치하여 추출한 후 농축하여 애엽 추출물과 연근 추출물을 제조하였다(실시예1 참조).In one embodiment of the present invention, 100 g of rosemary or lotus root was added to 1 L of water or 80% ethanol, extracted at 24 ° C. for 24 hours, and concentrated to prepare a leaf extract and lotus root extract (see Example 1).
조성물에 함유되는 애엽 추출물과 연근 추출물은 분말 혹은 추출액의 형태로 사용될 수 있으며 그 양 및 비율은 추출에 사용되는 애엽 및 연근의 양, 추출 농축 정도 및 용도에 따라 다양하게 조절 할 수 있다. 예를 들면 상기 본 발명의 조성물 은 애엽 추출물과 연근 추출물이 1 : 0.1 내지 10의 비율로 혼합된 상태로 사용 될 수 있으며 바람직하게는 1 : 0.5 내지 2의 비율로 혼합된 상태로 사용될 수 있으며 가장 바람직하게는 애엽 추출물과 연근 추출물이 1:1의 비율로 혼합된 상태로 사용될 수 있다.The leaf extract and lotus root extract contained in the composition may be used in the form of powder or extract, and the amount and ratio may be variously adjusted according to the amount of leaf and lotus root used for extraction, the degree of extract concentration, and the use. For example, the composition of the present invention may be used in a state in which the leaf extract and lotus root extract are mixed in a ratio of 1: 0.1 to 10, preferably in a mixed ratio of 1: 0.5 to 2, and most Preferably the leaf extract and lotus root extract may be used in a mixed ratio of 1: 1.
본 발명의 조성물은 위염 예방, 개선 또는 치료 효과를 보이는 것을 특징으로 한다.The composition of the present invention is characterized by showing the effect of preventing, improving or treating gastritis.
본 발명의 조성물의 위염 예방, 개선 또는 치료 효과는 흰쥐를 이용한 일실시예에서 확인되었다.Gastritis prevention, improvement or treatment effect of the composition of the present invention was confirmed in one embodiment using a rat.
본 발명의 일실시예에서는 애엽추출물과 연근추출물을 1대 1의 비율로 혼합한 혼합조성물을 흰쥐에 경구투여방식으로 투여하여 수침구속에 의한 스트레스성 위염의 발생을 억제하는지 여부를 스트레스를 준 후 흰쥐의 위를 해부하여 확인하였다. 그 결과 대조군의 경우 해부한 위에서 위궤양이 다수 발견되었으나 본 발명의 혼합조성물을 투여한 경우 그 정도가 월등히 떨어진 것을 확인하였다. 또한 이는 애엽 추출물 또는 연근 추출물을 단독으로 투여한 군에 비하여서도 그 억제 능력이 월등한 것임을 확인하였다(실시예 2 참조).In one embodiment of the present invention by administering oral administration to the rat mixed composition of leaf extract and lotus root extract in a ratio of 1 to 1 after stressing whether or not to suppress the occurrence of stress gastritis due to water restraint The stomach of the rat was dissected and confirmed. As a result, a large number of gastric ulcers were found in the dissected stomach in the control group, but when the mixed composition of the present invention was administered, the degree was significantly reduced. In addition, it was confirmed that the inhibitory ability is superior to the group administered alone or lotus root extract alone (see Example 2).
따라서 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물을 제공한다.Therefore, the present invention provides a pharmaceutical composition for preventing or treating gastritis, which contains a leaf extract and lotus root extract as an active ingredient.
본 발명에 따른 약학적 조성물은 애엽 추출물 및 연근 추출물의 혼합 조성물을 단독으로 함유하거나 또는 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 함유할 수 있다.The pharmaceutical composition according to the present invention may contain a mixed composition of leaf extract and lotus root extract alone or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.
약학적으로 허용되는 담체로는 예컨대, 경구 투여용 담체 또는 비경구 투여용 담체를 추가로 포함할 수 있다. 경구 투여용 담체는 락토스, 전분, 셀룰로스 유도체, 마그네슘 스테아레이트, 스테아르산 등을 포함할 수 있다. 아울러, 펩티드 제제에 대한 경구투여용으로 사용되는 다양한 약물전달물질을 포함할 수 있다. 또한, 비경구 투여용 담체는 물, 적합한 오일, 식염수, 수성 글루코오스 및 글리콜 등을 포함할 수 있으며, 안정화제 및 보존제를 추가로 포함할 수 있다. 적합한 안정화제로는 아황산수소나트륨, 아황산나트륨 또는 아스코르브산과 같은 항산화제가 있다. 적합한 보존제로는 벤즈알코늄 클로라이드, 메틸- 또는 프로필-파라벤 및 클로로부탄올이 있다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현택제 등을 추가로 포함할 수 있다. 그 밖의 약학적으로 허용되는 담체로는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있다(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In addition, it may include a variety of drug delivery materials used for oral administration to the peptide formulation. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent and the like in addition to the above components. Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).
본 발명의 조성물은 인간을 비롯한 포유동물에 어떠한 방법으로도 투여할 수 있다. 예를 들면, 경구 또는 비경구적으로 투여할 수 있다. 비경구적인 투여방법으로는 이에 한정되지는 않으나, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장내 투여일 수 있다.The composition of the present invention may be administered to any mammal, including humans. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration. Can be.
본 발명의 약학적 조성물은 상술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다.The pharmaceutical composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
경구 투여용 제제의 경우에 본 발명의 조성물은 분말, 과립, 정제, 환제, 당의정제, 캡슐제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 등으로 당업계에 공지된 방법을 이용하여 제형화될 수 있다. 예를 들어, 경구용 제제는 활성성분을 고체 부형제와 배합한 다음 이를 분쇄하고 적합한 보조제를 첨가한 후 과립 혼합물로 가공함으로써 정제 또는 당의정제를 수득할 수 있다. 적합한 부형제의 예로는 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨 및 말티톨 등을 포함하는 당류와 옥수수 전분, 밀 전분, 쌀 전분 및 감자 전분 등을 포함하는 전분류, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸-셀룰로즈 등을 포함하는 셀룰로즈류, 젤라틴, 폴리비닐피롤리돈 등과 같은 충전제가 포함될 수 있다. 또한, 경우에 따라 가교결합 폴리비닐피롤리돈, 한천, 알긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있다. 나아가, 본 발명의 약학적 조성물은 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and the like. Can be. For example, oral formulations can be obtained by tablets or dragees by combining the active ingredients with solid excipients, milling them, adding suitable auxiliaries and then processing them into granule mixtures. Examples of suitable excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch, cellulose, including starch, corn starch, wheat starch, rice starch and potato starch, etc. Fillers such as celluloses, gelatin, polyvinylpyrrolidone, and the like, including methyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose, and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.
비경구 투여용 제제의 경우에는 주사제, 크림제, 로션제, 외용연고제, 오일 제, 보습제, 겔제, 에어로졸 및 비강 흡입제의 형태로 당업계에 공지된 방법으로 제형화할 수 있다. 이들 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995)에 기재되어 있다.Formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, humectants, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995, a prescription generally known in all pharmaceutical chemistries.
본 발명의 약학적 조성물의 총 유효량은 단일 투여량(single dose)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple dose)으로 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 본 발명의 약학적 조성물은 질환의 정도에 따라 유효성분의 함량을 달리할 수 있다. 바람직하게 본 발명의 조성물의 바람직한 전체 용량은 1일당 환자 체중 1㎏ 당 약 0.01㎍ 내지 500mg, 가장 바람직하게는 0.1㎍ 내지 100mg일 수 있다. 그러나 상기 조성물의 용량은 약학적 조성물의 투여 경로 및 치료 횟수뿐만 아니라 환자의 연령, 체중, 건강 상태, 성별, 질환의 중증도, 식이 및 배설율 등 다양한 요인들을 고려하여 환자에 대한 유효 투여량이 결정되는 것이므로, 이러한 점을 고려할 때 당 분야의 통상적인 지식을 가진 자라면 상기 조성물을 위염의 예방 또는 치료제로서의 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다. 본 발명에 따른 약학적 조성물은 본 발명의 효과를 보이는 한 그 제형, 투여 경로 및 투여 방법에 특별히 제한되지 아니한다.The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol which is administered in multiple doses for a long time. . The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease. Preferably the preferred total dose of the composition of the present invention may be about 0.01 μg to 500 mg, most preferably 0.1 μg to 100 mg per kg of patient body weight per day. However, the dosage of the composition is determined in consideration of various factors such as the age, weight, health condition, sex, severity of the disease, diet and excretion rate, as well as the route and frequency of treatment of the pharmaceutical composition is determined In view of this, one of ordinary skill in the art will be able to determine the appropriate effective dosage for the particular use of the composition as a prophylactic or therapeutic agent for gastritis. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
또한 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 개선용 식품 조성물을 제공한다.In another aspect, the present invention provides a food composition for preventing or improving gastritis containing the leaf extract and lotus root extract as an active ingredient.
본 발명의 식품 조성물은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함할 수 있다. The food composition of the present invention includes ingredients that are commonly added in food production, and may include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents.
탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 드링크 제로 제조되는 경우에는 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다. 식품에 대한 용이한 접근성을 고려한다면, 본 발명의 식품 조성물은 위염 예방 및 개선에 매우 유용하다.Examples of carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when manufactured with a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract, licorice extract, and the like may be further included. Given the ease of access to food, the food composition of the present invention is very useful for preventing and improving gastritis.
본 발명의 조성물은 상술한 바와 같은 효능을 나타낼 뿐만 아니라, 생약 추출물을 유효 성분으로 포함하고 있기 때문에, 인체에 대한 부작용이 화학적 합성 조성물보다 극히 적다.Since the composition of the present invention not only exhibits the above-mentioned efficacy, but also contains the herbal extract as an active ingredient, the side effects on the human body are extremely less than that of the chemical synthetic composition.
본 발명의 식품 조성물 중 애엽 추출물과 연근 추출물의 혼합 조성물의 바람직한 함유량으로는 전체 중량에 대하여 약 0.1~50중량%를 포함할 수 있다. 바람직 하게는 0.5mg/kg/day~5mg/kg/day의 양으로 섭취하는 경우 위염 예방 및 개선 효과가 나타날 수 있다. The preferred content of the mixed composition of the leaf extract and lotus root extract in the food composition of the present invention may include about 0.1 to 50% by weight relative to the total weight. Preferably intake of 0.5mg / kg / day ~ 5mg / kg / day in the amount of gastritis can be prevented and improved.
또한 본 발명의 조성물은 항균활성을 보이는 것을 특징으로 한다.In addition, the composition of the present invention is characterized by showing an antimicrobial activity.
본 발명의 조성물의 항균 효과는 본 발명의 일실시예에서 유해미생물을 이용한 항균력 실험에 의해 확인되었다.The antimicrobial effect of the composition of the present invention was confirmed by an antimicrobial activity test using harmful microorganisms in one embodiment of the present invention.
본 발명의 일실시예에서는 클렙시엘라 뉴모니에를 한천배지에 접종 한 후 본 디스크 페이퍼를 놓고 여기에 애엽추출물과 연근추출물을 1대 1의 비율로 혼합한 혼합조성물을 투여하여 유해미생물의 배양 억제 환을 형성하는지 여부를 관찰하였다. 그 결과 애엽 추출물 또는 연근 추출물을 단독으로 투여한 군에 비하여 그 억제 능력이 월등히 뛰어남을 확인하였다(실시예 3 참조).In one embodiment of the present invention inoculated Klebsiella pneumoniae in agar medium and then placed on the disk paper and administered to the mixed composition mixed the leaf extract and lotus root extract in a ratio of 1 to 1 culture of harmful microorganisms It was observed whether or not a suppressive ring was formed. As a result, it was confirmed that the inhibitory ability is significantly superior to the group administered with the leaf extract or lotus root extract alone (see Example 3).
따라서 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 항균 조성물을 제공한다.Therefore, it provides an antimicrobial composition containing the leaf extract and lotus root extract as an active ingredient.
본 발명의 조성물은 유해미생물에 대하여 항균효과가 우수하며, 특히 클렙시엘라 뉴모니에(Klebsiella pneumoniae)에 대하여 우수한 항균활성을 가진다.The composition of the present invention has an excellent antimicrobial effect against harmful microorganisms, and particularly has an excellent antimicrobial activity against Klebsiella pneumoniae.
또한 본 발명의 조성물은 식용, 약용으로 사용되는 식물에서 추출한 것이므 로 인체에 무해하며, 장기간 사용에 따른 부작용이 발생하지 않는다.In addition, the composition of the present invention is harmless to the human body because it is extracted from plants used for edible, medicinal, and does not cause side effects from long-term use.
본 발명의 항균용 조성물은 수액제, 고형제, 분말제, 유액제, 젤형 또는 캅셀제가 바람직하나 사용 용도에 따라 달리 적용될 수 있다. 항균성 조성물은 1일 0.000001 내지 1000 mg으로 1회 내지 3회 실시하는 것이 바람직하나, 사용용도 및 적용부위의 상태에 따라 조절하는 것이 더욱 바람직하다.The antimicrobial composition of the present invention is preferably a fluid, a solid, a powder, an emulsion, a gel or a capsule, but may be applied differently depending on the intended use. The antimicrobial composition is preferably carried out once to three times at 0.000001 to 1000 mg per day, but more preferably adjusted according to the state of use and application site.
따라서, 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물, 위염 예방 또는 개선용 식품 조성물 또는 항균 조성물을 제공한다. 본 발명의 조성물은 스트레스로 인한 위염, 위궤양 치료 효능이 뛰어나므로 위염, 위궤양 예방, 개선 또는 치료를 위한 의약품 또는 식품 제조에 사용이 가능하며 클렙시엘라 뉴모니에에 대한 항균 능력이 뛰어나 화장품, 소독제, 세정제 및 식품보존제의 형태로 유용하게 사용될 수 있다.Accordingly, the present invention provides a pharmaceutical composition for preventing or treating gastritis, a food composition for preventing or improving gastritis, or an antimicrobial composition containing the leaf extract and lotus root extract as an active ingredient. Since the composition of the present invention is excellent in treating gastritis and gastric ulcer due to stress, it can be used in the manufacture of medicines or foods for the prevention, improvement or treatment of gastritis and gastric ulcer, and has excellent antibacterial ability against Klebsiella pneumoniae cosmetics and disinfectants. It can be usefully used in the form of detergents, food preservatives.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<실시예 1> ≪ Example 1 >
애엽 및 연근 추출물 제조Preparation of Leafy and Lotus Root Extracts
애엽(Artemisia argyi Levl. et vant)은 경동시장에서 건조되어 약재용으로 세절된 것을 구입하였으며 연근은 흑석동 시장에서 구입하여 건조한 후 세절하여 사용하였다.The leaves of Artemisia argyi Levl. Et vant were dried at Gyeongdong market and sliced for medicinal use. Lotus root was purchased at Heukseok-dong market and dried and then used.
<1-1> 애엽 및 연근의 물 추출물 제조<1-1> Preparation of Water Extracts of Lotus Leaf and Lotus Root
1차 증류수 1000ml에 애엽 또는 연근 100g을 넣고 24℃에서 24시간 동안 방치하여 추출하였다. 상기 추출물을 여과지(Whatman filter paper)를 사용하여 슬러지와 용액을 분리하고 분리한 용액을 95℃의 온도에서 중탕하여 4배 농축하여 사용하였다.100 g of leaflets or lotus root was added to 1000 ml of first distilled water, and the mixture was left at 24 ° C. for 24 hours to extract the extract. The extract was separated from the sludge and the solution by using a filter paper (Whatman filter paper), and the separated solution was used by condensing at a temperature of 95 ° C. and concentrating 4 times.
<1-2> 애엽 및 연근의 에탄올 추출물 제조<1-2> Preparation of Ethanol Extracts of Larvae and Lotus Roots
80% 에탄올 1000ml에 애엽 또는 연근 100g을 혼합한 후 24℃에서 24시간 동안 방치하여 추출하였다. 상기 추출물을 여과지(Whatman filter paper)를 사용하여 슬러지와 용액을 분리하고 분리된 용액에서 에탄올을 제거하기 위하여 농축기(Evaporator, Heidolph vv 2000)를 사용하여 38℃에서 4배 농축하였다.1000g of 80% ethanol was mixed with 100g of leafy or lotus root, and then extracted by standing at 24 ° C for 24 hours. The extract was concentrated 4 times at 38 ° C. using a concentrator (Evaporator, Heidolph vv 2000) to separate the sludge and the solution using Whatman filter paper and remove ethanol from the separated solution.
<실시예 2> <Example 2>
애엽 추출물과 연근 추출물의 혼합조성물의 위염 예방 효과 실험Experimental Effect of Gastritis on the Combination of Rosemary and Lotus Root Extracts
실험에는 스프라그-도올리(Sprague-Dawley) 수컷 흰쥐(rat, 샘타코, 한국)를 사용하였다. 하루 밤 동안 단식 시킨 후 흰쥐 25마리를 총 5개의 군으로 나누어 실험하였다. 각 군별로 처리할 조건은 하기 표 1과 같다.Sprague-Dawley male rats (rat, Samtako, Korea) were used for the experiment. After fasting overnight, 25 rats were divided into 5 groups. Conditions to be treated by each group are shown in Table 1 below.
추출물은 실시예 1에서 추출한 물 추출물을 사용하였으며 경구투여방식으로 투여하였다. 대조군의 경우 추출물 대신 물을 투여하였다. 총 7일간 투여 후 A, B, C, D 그룹의 흰쥐를 대상으로 스트레스를 주어 위염을 일으키는 실험을 하였다. The extract was used as the water extract extracted in Example 1 and administered by oral administration. For the control group, water was administered instead of the extract. After 7 days of administration, rats in groups A, B, C, and D were stressed and tested to cause gastritis.
흰쥐에 스트레스를 주어 위염을 발생시키는 방법은 수침구속 스트레스모델(WIR, Water Immersion-Restraint) 방법을 이용하였다(Brzozowski T, et al, J. Physiol. Pharmacol. 2007 Dec;58 Suppl 6:53-64).The stress-induced gastritis in rats was determined using the Water Immersion-Restraint (WIR) method (Brzozowski T, et al, J. Physiol. Pharmacol. 2007 Dec; 58 Suppl 6: 53-64). ).
실험용 흰쥐를 철사 케이지에 넣어 움직일 수 없도록 행동에 제한을 준 후 케이지를 23℃ 항온수조에 넣어 3시간 동안 스트레스를 주어 위염이 일어나게 하였다.The experimental rats were placed in a wire cage to restrict their behavior and the cage was placed in a 23 ° C. water bath for 3 hours to cause gastritis.
수침구속에 의한 스트레스를 준 후 쥐를 경추탈구로 희생시켜 위를 적출하였다. 적출한 위를 해부하여 위 점막에 형성된 궤양의 넓이를 측정하여 각 군의 평균을 구하였다.After stress-induced restraint, rats were sacrificed by cervical dislocation and the stomach was extracted. The isolated stomach was dissected and the area of ulcers formed on the gastric mucosa was measured, and the mean of each group was calculated.
그 결과 상기 표 2 또는 도 5에서 보는 바와 같이, 본 발명의 애엽 추출물과 연근 추출물의 혼합조성물 투여한 군(D)이 위궤양 발생을 가장 효과적으로 억제하는 것을 확인하였다. 육안 관찰에 의하여서도 도 1내지 4에서 보는 바와 같이, 대조군(A)의 경우 위궤양이 매우 많이 관찰되었으며, 애엽 추출물과 연근 추출물의 혼합조성물 투여한 군(D)에서는 위궤양이 거의 관찰되지 않는 것을 확인하였다. 이는 애엽 추출물이나 연근 추출물을 단독으로 투여한 군과 비교하여도 월등히 위궤양 발생이 줄어든 것임을 확인하였다.As a result, as shown in Table 2 or Figure 5, it was confirmed that the group (D) administered the mixed composition of the leaf extract and lotus root extract of the present invention most effectively suppress the occurrence of gastric ulcer. As shown in FIGS. 1 to 4 by visual observation, gastric ulcer was observed in the case of the control group (A) very much, and gastric ulcer was hardly observed in the group (D) administered with the mixed composition of the leaf extract and lotus root extract. It was. It was confirmed that the incidence of gastric ulcers was significantly reduced compared to the group administered alone or lotus root extract.
수침구속에 의한 스트레스를 주지 아니한 흰쥐 그룹(E)의 경우 위궤양이 발생하지 않았다(결과미도시).Gastric ulceration did not occur in the rat group (E), which was not stressed by immersion restraint (results not shown).
이로서 본 발명의 혼합조성물은 위궤양 예방 및 치료 효과가 우수한 것을 알 수 있었으며 이러한 효과는 애엽추출물이나 연근 추출물을 단독으로 처리한 경우보다도 월등히 우수함을 확인하였다.As a result, the mixed composition of the present invention was found to be excellent in the prevention and treatment of gastric ulcers, it was confirmed that this effect is significantly superior to the case of treating only leaf extract or lotus root extract alone.
<실시예 3> <Example 3>
애엽 추출물과 연근 추출물의 혼합조성물의 항균력 효과 실험Antimicrobial Effect of Mixed Composition of Leafy Leaf Extract and Lotus Root Extract
애엽 추출물, 연근 추출물 및 이들의 혼합 조성물의 클렙시엘라 뉴모니에에 대한 항균력을 조사하기 위하여 뉴트리언트 한천배지(박토 펩톤 5.0g, 소고기추출물 1.0g, 효모추출물 2.0g, 염화나트륨 5.0g, 아가 15g/증류수 1L)에 표 3의 10 종의 유해 미생물을 각각 접종하여 37℃에서 24시간 배양하였다. 상기 배양된 균체들을 배지로부터 긁어모아 인산완충액(PBS, pH 7.4)으로 2회 세척하고 인산완충액에 1%로 현탁하여 사용하였다.In order to investigate the antimicrobial activity of leafy leaf extract, lotus root extract and their mixed composition against Klebsiella pneumoniae (Nutrient agar medium (bacto peptone 5.0g, beef extract 1.0g, yeast extract 2.0g, sodium chloride 5.0g, agar 15g) / 1L distilled water) was inoculated each of the 10 kinds of harmful microorganisms in Table 3 and incubated at 37 ℃ for 24 hours. The cultured cells were scraped from the medium, washed twice with phosphate buffer (PBS, pH 7.4) and suspended in phosphate buffer at 1%.
억제환 측정을 위하여 뉴트리언트 한천배지에 상기 클렙시엘라 뉴모니에 현탁액을 플레이트당 균수가 2 X 108이 되도록 조절한 다음 60℃의 굳지 않은 영양한천배지 13㎖와 함께 1000mm 페트리디쉬에 부은 후 잘 굳혔다. 그 다음 56℃ 배양기에서 24시간 동안 건조시켜 완전히 습기를 제거한 10mm 페이퍼 디스크(Toyo Roshi Kaisha, Ltd, Japan)3개씩을 상기 플레이트 위에 올려놓은 다음 각각의 디스크에 애엽 추출물, 연근 추출물 및 이들의 혼합 조성물을 각각 100㎕ 씩 투여하여 37℃에서 12시간 동안 배양하여 억제 환을 형성하는지 여부를 관찰하였다.To determine the inhibition of the ring, the Klebsiella pneumoniae suspension was adjusted to 2 x 10 8 cells per plate on nutrient agar medium and poured into 1000 mm Petri dishes with 13 ml of nutrient agar medium at 60 ° C. Hardened well Then, three 10 mm paper disks (Toyo Roshi Kaisha, Ltd, Japan) completely dried and dried in a 56 ° C. incubator for 24 hours were placed on the plate, and then the leaf extracts, lotus root extracts, and mixed compositions thereof were placed on each disk. 100 μl of each of which was incubated at 37 ° C. for 12 hours to observe whether or not an inhibitory ring was formed.
그 결과 도 6 또는 7에서 보는 바와 같이, 본 발명의 혼합 조성물은 클렙시엘라 뉴모니에에 있어서 연근 또는 애엽 추출물보다 항균력이 우수한 것으로 확인되었다.As a result, as shown in Figure 6 or 7, it was confirmed that the mixed composition of the present invention is superior to the antibacterial activity of lotus root or leaf leaf extract in Klebsiella pneumoniae.
이상 살펴본 바와 같이, 본 발명은 애엽 추출물 및 연근 추출물을 유효성분으로 함유하는 위염 예방 또는 치료용 약학적 조성물, 위염 예방 또는 개선용 식품 조성물 또는 항균 조성물을 제공한다. 본 발명의 조성물은 스트레스로 인한 위염, 위궤양 치료효능이 뛰어나므로 위염 위궤양 예방, 개선 또는 치료를 위한 의약품 또는 식품 제조에 사용이 가능하며 클렙시엘라 뉴모니에에 대한 항균 능력이 뛰어나 화장품, 소독제, 세정제 및 식품보존제의 형태로 유용하게 사용될 수 있어 산업상 이용가능성이 높다.As described above, the present invention provides a pharmaceutical composition for preventing or treating gastritis, a food composition for preventing or improving gastritis, or an antimicrobial composition containing the leaf extract and lotus root extract as an active ingredient. Since the composition of the present invention is excellent in treating gastritis and gastric ulcer due to stress, it can be used in the manufacture of medicines or foods for the prevention, improvement or treatment of gastritis gastritis, and has excellent antibacterial ability against Klebsiella pneumoniae, cosmetics, disinfectants, It can be usefully used in the form of detergents and food preservatives, it is highly industrially applicable.
도 1은 애엽 추출물을 투여한 군의 스트레스성 위염을 유발시킨 흰쥐의 위장 해부 사진이다.Figure 1 is a picture of the stomach anatomy of the rats that caused stress gastritis of the group administered the lobar extract.
도 2는 연근 추출물을 투여한 군의 스트레스성 위염을 유발시킨 흰쥐의 위장 해부 사진이다.Figure 2 is a picture of the gastrointestinal dissection of the rats induced stress gastritis of the group administered lotus root extract.
도 3은 애엽 추출물과 연근 추출물의 혼합 조성물을 투여한 군의 스트레스성 위염을 유발시킨 흰쥐의 위장 해부 사진이다.Figure 3 is a gastrointestinal dissection of the rats that caused stress gastritis of the group administered a mixed composition of the leaf extract and lotus root extract.
도 4는 물을 투여한 군의 스트레스성 위염을 유발시킨 흰쥐의 위장 해부 사진이다.Figure 4 is a picture of the gastrointestinal dissection of the rats that caused stress gastritis of the group administered with water.
도 5는 애엽 추출물, 연근 추출물 및 이들의 혼합 조성물을 투여한 후 스트레스성 위염을 유발시킨 흰쥐의 위장내 위궤양 유발 면적을 비교한 그래프이다.Figure 5 is a graph comparing the gastrointestinal ulcer induced area of the rats that induced stress gastritis after administration of the leaf extract, lotus root extract and their mixed composition.
도 6은 본 발명의 조성물의 클렙시엘라 뉴모니에에 대한 항균활성을 비교 시험한 사진이다.Figure 6 is a photograph comparing the antimicrobial activity of the composition of the present invention Klebsiella pneumoniae.
도 7은 본 발명의 조성물, 애엽 추출물 및 연근 추출물의 클렙시엘라 뉴모니에에 대한 항균활성을 생육억제환의 크기로 비교한 그래프이다(Y축 : 생육 억제환의 넓이).Figure 7 is a graph comparing the antimicrobial activity of Klebsiella pneumoniae of the composition of the present invention, leaf extract and lotus root extract by the size of the growth inhibitory ring (Y-axis: the width of the growth inhibitory ring).
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090090408A KR100967832B1 (en) | 2009-09-24 | 2009-09-24 | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090090408A KR100967832B1 (en) | 2009-09-24 | 2009-09-24 | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR100967832B1 true KR100967832B1 (en) | 2010-07-07 |
Family
ID=42645158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090090408A KR100967832B1 (en) | 2009-09-24 | 2009-09-24 | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100967832B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016208926A1 (en) * | 2015-06-24 | 2016-12-29 | 대원제약주식회사 | Pharmaceutical composition comprising isopropanol extract of artemisiae argyi folium |
| KR102203168B1 (en) | 2020-08-19 | 2021-01-15 | 주식회사 바이오뷰텍 | Method for production of o/w gel cream with high content of ethanol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0127777B1 (en) * | 1994-01-06 | 1998-04-01 | 이은방 | Antigastritic and antiulcer containing eqpatilin |
| KR20060002639A (en) * | 2004-07-03 | 2006-01-09 | 동아제약주식회사 | Dicoumarol-removed-extract of artemisia, preparation and pharmaceutical compositions thereof |
-
2009
- 2009-09-24 KR KR1020090090408A patent/KR100967832B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0127777B1 (en) * | 1994-01-06 | 1998-04-01 | 이은방 | Antigastritic and antiulcer containing eqpatilin |
| KR20060002639A (en) * | 2004-07-03 | 2006-01-09 | 동아제약주식회사 | Dicoumarol-removed-extract of artemisia, preparation and pharmaceutical compositions thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016208926A1 (en) * | 2015-06-24 | 2016-12-29 | 대원제약주식회사 | Pharmaceutical composition comprising isopropanol extract of artemisiae argyi folium |
| KR102203168B1 (en) | 2020-08-19 | 2021-01-15 | 주식회사 바이오뷰텍 | Method for production of o/w gel cream with high content of ethanol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3991742A1 (en) | Coronavirus therapeutic agent comprising elaeocarpus sylvestris extract as active ingredient | |
| Meher et al. | Pharmacological profile of Terminalia chebula Retz. and Willd.(Haritaki) in Ayurveda with evidences | |
| JP2003342190A (en) | Anti-helicobacter pylori composition | |
| KR20190008967A (en) | Oral spray containing Ixeris dentata extract for preventing or treating xerostomia caused by diabete | |
| KR20140126661A (en) | Composition containing complex extracts for preventing, improving or treating colitis | |
| KR101384633B1 (en) | A composition for treating or preventing toxoplasmosis comprising Zingiber officinale extract and fractions thereof | |
| KR100967832B1 (en) | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient | |
| Aswin et al. | Abrus precatorius: A comprehensive insight into the phytochemical, pharmacological, therapeutic activities and safety | |
| KR101851167B1 (en) | Pharmaceutical composition containing extract of Spiraea prunifolia for prevention and treatment of allergic diease | |
| KR102016077B1 (en) | Food compositions for improving and preventing atopic dematitis skin condition | |
| KR100847440B1 (en) | Drug of herbal mixture for treating or preventing inflammatory diseases | |
| KR101811848B1 (en) | Composite comprising curcuminoid/stevioside for prevention or treatment of influenza virus | |
| KR102551499B1 (en) | Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Agrimonia pilosa as an active ingredient | |
| WO2022186414A1 (en) | Anti-inflammatory composition comprising epimendium koreanum nakai, polygala tenuifolia wild, and polyporus umbellatus fries extracts or mixture thereof as active ingredient | |
| KR20120017811A (en) | Antibacterial composition against helicobacter pylori comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient | |
| KR20220094308A (en) | Pharmaceutical composition for preventing or treating infectious symptoms by pathogenic microorganism comprising Cichorium intybus extract as an active ingredient | |
| KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR20170003153A (en) | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| KR102507928B1 (en) | Composition for preventing or treating nasal polyp comprising extract of sargassum horneri | |
| Tiwari et al. | Preliminary phytochemical investigation of alcoholic extract of Bauhinia Vahlii | |
| KR102001769B1 (en) | A Composition comprising extracts, fractions or isolated compounds of Liriope platyphylla for inhibition of Hepatitis E virus proliferation | |
| KR102019974B1 (en) | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion | |
| KR20070087951A (en) | Composition comprising the extract of acp mixed crude drugs for preventing and treating arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20121226 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20140530 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20150624 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20160624 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20170621 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20180627 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 10 |